Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
2(22%)
Results Posted
67%(4 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_4
1
11%
Ph early_phase_1
2
22%
Ph phase_2
2
22%
Ph phase_1
3
33%
Ph phase_3
1
11%

Phase Distribution

5

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Early Phase 1First-in-human
2(22.2%)
Phase 1Safety & dosage
3(33.3%)
Phase 2Efficacy & side effects
2(22.2%)
Phase 3Large-scale testing
1(11.1%)
Phase 4Post-market surveillance
1(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

2

trials recruiting

Total Trials

9

all time

Status Distribution
Active(2)
Completed(6)
Terminated(1)

Detailed Status

Completed6
Recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
2
Success Rate
85.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (22.2%)
Phase 13 (33.3%)
Phase 22 (22.2%)
Phase 31 (11.1%)
Phase 41 (11.1%)

Trials by Status

completed667%
recruiting222%
terminated111%

Recent Activity

2 active trials
Showing 5 of 9
recruitingphase_3

Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)

NCT07457918
recruitingearly_phase_1

Investigation of the Distinct Mechanisms Involved in Inflammatory Resolution Between Healthy Men and Women

NCT05597098
terminatedphase_1

First-time-in-Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single (in Both Fed and Fasted States) or Repeat Doses of GSK3358699

NCT03426995
completedphase_1

Lipopolysaccharide (LPS) or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Challenge Study on Healthy Subjects

NCT03306589
completedphase_2

Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2

NCT03017846
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07457918Phase 3

Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)

Recruiting
NCT05597098Early Phase 1

Investigation of the Distinct Mechanisms Involved in Inflammatory Resolution Between Healthy Men and Women

Recruiting
NCT03426995Phase 1

First-time-in-Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single (in Both Fed and Fasted States) or Repeat Doses of GSK3358699

Terminated
NCT03306589Phase 1

Lipopolysaccharide (LPS) or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Challenge Study on Healthy Subjects

Completed
NCT03017846Phase 2

Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2

Completed
NCT03625960Phase 4

Cantharone for the Treatment of Perenial Warts

Completed
NCT01026064Phase 1

Cantharidin-induced Skin Blister for Testing Anti-inflammatory Effects of Macrolides

Completed
NCT01582321Early Phase 1

Investigation of the Influence of Gender on Cardiovascular Function

Completed
NCT02665260Phase 2

Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum

Completed

All 9 trials loaded

Drug Details

Intervention Type
COMBINATION PRODUCT
Total Trials
9